2020年3月2日

B係列投資由西海岸投資者Foresite Capital主導，所有現有投資者均參與該融資。該投資將用於加速公司基因合成平台的開發，直至推出首批產品。2020年3月2日美國東部標準時間淩晨02:00英國劍橋——(美國商業資訊)——EVONETIX LTD(“EVONETIX”)是一家合成生物學公司，開發可擴展、高保真和快速基因合成的桌麵平台。今天宣布成功完成B輪融資。該公司在本輪融資中籌集了3000萬美元(2300萬英鎊)，由新投資者Foresite Capital領投。現有投資者Draper Esprit、DCVC (Data Collective)、Morningside集團、Providence Investment Company、Cambridge Consultants Ltd、Rising Tide Fund和Civilization Ventures也都參與了這輪融資。新的資金將用於加速內部技術開發，包括整合Evonetix的技術，使芯片上的DNA合成成為可能。這筆投資將資助公司引入其桌麵DNA平台，該平台一旦完全開發，將促進和實現快速增長的合成生物學領域，應用於包括醫療保健、製藥、生物技術、食品和農業以及數據存儲在內的各個行業。這筆投資還將支持公司的重要招聘計劃，因為它將繼續增加位於英國劍橋Coldhams Business Park的Evonetix最先進設施的科學、運營和商業員工人數。Evonetix成立於2015年，致力於開發在矽陣列上並行合成DNA的技術，以促進快速發展的合成生物學領域，該領域對高通量和高精度DNA合成的需求不斷增加。該公司由劍橋谘詢公司和普羅維登斯投資有限公司成立，並於2018年完成了1230萬美元的A輪融資，此外還獲得了Innovate UK的撥款。B輪融資的結束使該公司迄今為止的總融資額達到4600萬美元。 The Company has the backing of the technology entrepreneur and venture capitalist Hermann Hauser. The Company’s technology utilises a silicon chip, made by microelectromechanical systems (MEMS) processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches. Dr Tim Brears, Evonetix CEO, said: “The backing of both our existing and new investors will enable us to fast track development, testing and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not possible with existing approaches.” Jim Tananbaum, CEO and Managing Director at Foresite Capital, said: “Evonetix is developing a desktop, short latency solution to synthesise DNA. We are delighted to support the team in their mission to make biological engineering as accessible and widespread as next-generation sequencing.” Vishal Gulati, Venture Partner, Draper Esprit, added: “The next set of breakthroughs in healthcare and synthetic biology will come from technologies that can go beyond reading DNA to writing it. Evonetix is leveraging the UK's strength in DNA research to build this unique, ground-breaking DNA synthesis platform. We’re excited to welcome Foresite Capital, one of the world's leading life-sciences investors, to support this Company to achieve the next stage of its growth and look forward to working closely with this talented team.” Armen Vidian, Evonetix Board member and Partner at DCVC, said: “DCVC is pleased to continue its commitment to synthetic biology with its renewed investment in Evonetix. As demand grows to use synthetic biology for everything from sustaining agriculture to creating precision medicines and synthetic fuels, Evonetix will be well-positioned to meet those more complex needs with highly accurate, high throughput, long-strand DNA synthesis.” For more information about Evonetix, please visit: www.evonetix.com or to learn more about the Company’s technology: www.evonetix.com/our-platform .